Johnson & Johnson to Expand its Dermatology Portfolio Through the Acquisition of Proteologix
Shots:
- Johnson & Johnson has agreed to acquire Proteologix to expand its dermatology portfolio for an aggregate of $850M in cash
- The acquisition adds Proteologix’s PX128, which will be entering P-I clinical evaluation to treat severe atopic dermatitis (AD) & moderate to severe asthma as well as PX130, currently under preclinical evaluation for moderate to severe AD, along with additional bispecific antibody programs for a range of diseases to J&J’s portfolio
- PX128 works by inhibiting IL-13-mediated Th2 skin inflammation and TSLP-mediated tissue inflammation while PX130 targets IL-13 similar to PX128 and IL-22, enabling restoration of skin barrier & preventing inflammation from allergens for treating AD & asthma
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related News:- Johnson & Johnson Highlights Data from the P-I Study of TAR-210 for Non-Muscle-Invasive Bladder Cancer (NMIBC) at AUA 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
